NICE recommends Lilly's mirikizumab (Omvoh) for the treatment of eligible adults with moderately to severely active ulcerative colitis

22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately ...

Read more →

PMPRB report shows increased plan costs, promising pharmaceutical innovation: expert

20 September 2023 - A recent report by the Patented Medicine Prices Review Board shows increased growth for private drug ...

Read more →

Updates to the Health Technology Assessment Policy and Methods Review Reference Committee – 22 September 2023

21 September 2023 - The agenda for this week's HTA Review Reference Committee meeting is now available. ...

Read more →

Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency

20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...

Read more →

Access to COVID-19 anti-viral treatments widened for more people at risk

20 September 2023 - PHARMAC is widening access to COVID-19 anti-virals to people who are vulnerable to severe infection from ...

Read more →

International HTA collaboration expands

20 September 2023 - The international collaboration between six health technology assessment bodies from across the UK, Australia and Canada ...

Read more →

How IQWiG assesses – version 7.0 of the method paper comes into force

19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...

Read more →

COVID-19 vaccine contract summary

18 September 2023 - The Ministry of Health has released a summary of the New Zealand Government’s procurement process for ...

Read more →

New form of fast-acting insulin added to the PBS

18 September 2023 - The Albanese Government is listing a new form of fast-acting insulin on the PBS from 1 ...

Read more →

Another uninformative update from the Health Technology Assessment Policy and Methods Review Reference Committee

15 September 2023 - The agenda for the HTA Review Reference Committee meeting of 14 September 2023 is now available. ...

Read more →

First treatment for acute migraine to be recommended by NICE set to benefit thousands

14 September 2023 - The first treatment to be recommended by NICE for treating acute migraine will soon be available on ...

Read more →

Here we go again - version 4

14 September 2023 - The Department has today published version 4 of the agenda for the November 2023 PBAC meeting. ...

Read more →

Paladin Labs announced favourable CADTH recommendation for Xcopri (cenobamate tablets)

12 September 2023 - Paladin Labs announced today that CADTH has recommended that Xcopri (cenobamate) be publicly reimbursed as adjunctive therapy ...

Read more →

Treatment options for people with glioma, a type of brain cancer

13 September 2023 - BMS, the supplier of lomustine, a treatment used for a type of brain cancer called glioma, is ...

Read more →

NICE issues two recommendations for UCB's inflammatory disease drug

11 September 2023 - NICE has issued final draft guidance recommending UCB's Bimzelx (bimekizumab), with the inflammatory disease drug now ...

Read more →